Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1990 Jul;81(1):72–75. doi: 10.1111/j.1365-2249.1990.tb05293.x

Autoantibodies to epithelial cells in patients on long-term therapy with leucocyte-derived interferon-alpha (IFN-alpha).

A Karlsson-Parra 1, P Burman 1, H Hagberg 1, K Oberg 1, G Alm 1, L Klareskog 1, F A Karlsson 1
PMCID: PMC1535027  PMID: 2199098

Abstract

During routine screening for anti-nuclear antibodies, using rat liver tissue as substrate, a reactivity against bile duct epithelium was observed in sera from carcinoid tumour patients given human leucocyte-derived IFN-alpha (HuLe IFN-alpha). In a retrospective study, initiated by this observation, the development of serum antibodies to bile duct epithelium was observed in nine out of 12 patients with carcinoid tumours and in three out of 14 patients with hairy-cell leukaemia during their treatment with HuLe IFN-alpha. However, no bile duct reactivity was observed in sera from carcinoid or hairy-cell leukaemia in patients given recombinant IFN-alpha. When analysing the reactivity of positive sera against a panel of rat and human tissues, a uniform reactivity was observed against simple epithelial cells lining the gastrointestinal tract, pancreatic secretory ducts, fallopian tube, kidney tubuli, mesothelium and also against carcinoid tumour cells. The mechanisms promoting autoreactivity against this simple epithelial cell autoantigen is so far unknown. The cytoplasmic as well as the restricted staining pattern of simple epithelial cells may indicate autoreactivity against certain cytoskeletal intermediate filaments, such as cytokeratin 19, 18 and 8, known to be exclusively present in simple epithelial cells and tumours derived from them.

Full text

PDF
72

Images in this article

74Fig. 1
on p.74
74Fig. 2
on p.74

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkins M. B., Mier J. W., Parkinson D. R., Gould J. A., Berkman E. M., Kaplan M. M. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med. 1988 Jun 16;318(24):1557–1563. doi: 10.1056/NEJM198806163182401. [DOI] [PubMed] [Google Scholar]
  2. Autoimmune thyroid disease in interferon-treated patients. Lancet. 1985 Jul 13;2(8446):100–101. [PubMed] [Google Scholar]
  3. Baldini L., Cortelezzi A., Polli N., Neri A., Nobili L., Maiolo A. T., Lambertenghi-Deliliers G., Polli E. E. Human recombinant interferon alpha-2C enhances the expression of class II HLA antigens on hairy cells. Blood. 1986 Feb;67(2):458–464. [PubMed] [Google Scholar]
  4. Burman P., Tötterman T. H., Oberg K., Karlsson F. A. Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J Clin Endocrinol Metab. 1986 Nov;63(5):1086–1090. doi: 10.1210/jcem-63-5-1086. [DOI] [PubMed] [Google Scholar]
  5. Cantell K., Hirvonen S. Large-scale production of human leukocyte interferon containing 10(8) units per ml. J Gen Virol. 1978 Jun;39(3):541–543. doi: 10.1099/0022-1317-39-3-541. [DOI] [PubMed] [Google Scholar]
  6. Fentiman I. S., Balkwill F. R., Thomas B. S., Russell M. J., Todd I., Bottazzo G. F. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol. 1988 Aug;24(8):1299–1303. doi: 10.1016/0277-5379(88)90219-2. [DOI] [PubMed] [Google Scholar]
  7. Hiscott J., Cantell K., Weissmann C. Differential expression of human interferon genes. Nucleic Acids Res. 1984 May 11;12(9):3727–3746. doi: 10.1093/nar/12.9.3727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miettinen M., Lehto V. P., Dahl D., Virtanen I. Varying expression of cytokeratin and neurofilaments in neuroendocrine tumors of human gastrointestinal tract. Lab Invest. 1985 Apr;52(4):429–436. [PubMed] [Google Scholar]
  9. Moll R., Franke W. W., Schiller D. L., Geiger B., Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982 Nov;31(1):11–24. doi: 10.1016/0092-8674(82)90400-7. [DOI] [PubMed] [Google Scholar]
  10. Oberg K., Funa K., Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983 Jul 21;309(3):129–133. doi: 10.1056/NEJM198307213090301. [DOI] [PubMed] [Google Scholar]
  11. Oberg K., Norheim I., Lind E., Alm G., Lundqvist G., Wide L., Jonsdottir B., Magnusson A., Wilander E. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep. 1986 Nov;70(11):1297–1304. [PubMed] [Google Scholar]
  12. Pfeffer L. M., Stebbing N., Donner D. B. Cytoskeletal association of human alpha-interferon-receptor complexes in interferon-sensitive and -resistant lymphoblastoid cells. Proc Natl Acad Sci U S A. 1987 May;84(10):3249–3253. doi: 10.1073/pnas.84.10.3249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Quesada J. R., Reuben J., Manning J. T., Hersh E. M., Gutterman J. U. Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med. 1984 Jan 5;310(1):15–18. doi: 10.1056/NEJM198401053100104. [DOI] [PubMed] [Google Scholar]
  14. Ratain M. J., Golomb H. M., Vardiman J. W., Vokes E. E., Jacobs R. H., Daly K. Treatment of hairy cell leukemia with recombinant alpha 2 interferon. Blood. 1985 Mar;65(3):644–648. [PubMed] [Google Scholar]
  15. Rhodes J., Ivanyi J., Cozens P. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur J Immunol. 1986 Apr;16(4):370–375. doi: 10.1002/eji.1830160410. [DOI] [PubMed] [Google Scholar]
  16. Trinchieri G., Santoli D., Koprowski H. Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins. J Immunol. 1978 Jun;120(6):1849–1855. [PubMed] [Google Scholar]
  17. Zoon K. C., Miller D., zur Nedden D., Hunkapiller M. W. Human leukocyte-derived alpha-interferons: purification and amino-terminal-amino-acid sequence of two components. J Interferon Res. 1982;2(2):253–260. doi: 10.1089/jir.1982.2.253. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES